Pyrazolyl pyrimidinone compounds and the uses thereof

Patent metadata

Field	Value
Publication number	US-12414949-B2
Application number	US-202318200419-A
Country	US
Kind code	B2
Filing date	May 22, 2023
Priority date	Oct 7, 2019
Publication date	Sep 16, 2025
Grant date	Sep 16, 2025

Abstract

The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.

First claim

What is claimed is:

1. A method for treatment of adenylyl cyclase-1 (AC-1) mediated pain or opioid dependence thereof, which comprises administering a therapeutically effective amount of a compound of Formula (I):

wherein:
R 1 is a C 1 -C 6 alkyl;
R 2 is a C 1 -C 6 alkyl; and
R 3 is an acyl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocyloalkyl, cycloalkenyl, heterocycloalkenyl, heterocyclyl; or an optionally substituted aryl, arylalkyl, or arylalkenyl;
wherein:
the compound of Formula (I) is a adenylyl cyclase-1 (AC-1) inhibitor:
the optionally substituted aryl, arylalkyl, or arylalkenyl, respectively, is further optionally substituted with optional substituents selected from a halogen group; hydroxyl group; alkoxy group; aryloxy group; aralkyloxy group; oxo(carbonyl) group; carboxylic acid group; carboxylate group; carboxylate ester group; sulfur atom containing groups selected from thiol, thioalkyl, aryl sulfide, sulfoxide, sulfone, sulfonyl or sulfonamide groups; or nitrogen atom containing groups selected from amines, azides, hydroxylamines, cyano, nitro groups, N-oxides, hydrazides, or enamines; or

a pharmaceutically acceptable salt thereof to a subject in need thereof.

2. The method according to claim 1 , wherein R 1 is ethyl and R 2 is methyl.

3. The method according to claim 1 , wherein said compound has a Formula (V):

wherein:
R 1 is a C 1 -C 6 alkyl;
R 2 is a C 1 -C 6 alkyl; and
R 5 represents five substituents groups on phenyl ring of Formula (V):
wherein:
each one of those five substituent groups of R 5 independently is a substituent selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; or

any two adjacent substituents defined as optional substituents of R 5 are taken together with the attached carbons to form an optionally substituted cyclic or heterocyclic moiety;
wherein:
each one of those five substituent groups of R 5 , the optionally substituted cyclic or heterocyclic moiety, respectively, is further optionally substituted with optional substituents selected from a halogen group; hydroxyl group; alkoxy group; aryloxy group; aralkyloxy group; oxo(carbonyl) group; carboxylic acid group; carboxylate group; carboxylate ester group; sulfur atom containing groups selected from thiol, thioalkyl, aryl sulfide, sulfoxide, sulfone, sulfonyl or sulfonamide groups; or nitrogen atom containing groups selected from amines, azides, hydroxylamines, cyano, nitro groups, N-oxides, hydrazides, or enamines; or

a pharmaceutically acceptable salt thereof to a subject in need thereof.

Assignees

• Purdue Research Foundation

Inventors

• Flaherty Daniel P
• Van Rijn Richard M
• Watts Val J
• Scott Jason A

Classifications

• C07D403/04 Primary

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61K31/506 Primary

  not condensed and containing further heterocyclic rings · CPC title